SG11202003943YA - Cd47 antigen-binding molecules - Google Patents

Cd47 antigen-binding molecules

Info

Publication number
SG11202003943YA
SG11202003943YA SG11202003943YA SG11202003943YA SG11202003943YA SG 11202003943Y A SG11202003943Y A SG 11202003943YA SG 11202003943Y A SG11202003943Y A SG 11202003943YA SG 11202003943Y A SG11202003943Y A SG 11202003943YA SG 11202003943Y A SG11202003943Y A SG 11202003943YA
Authority
SG
Singapore
Prior art keywords
antigen
binding molecules
molecules
binding
Prior art date
Application number
SG11202003943YA
Inventor
Jerome Douglas Boyd-Kirkup
Dipti Thakkar
Piers Ingram
Zhihao Wu
Konrad Paszkiewicz
Peter Brauer
Siyu Guan
Original Assignee
Hummingbird Bioscience Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1718101.7A external-priority patent/GB201718101D0/en
Priority claimed from GBGB1720425.6A external-priority patent/GB201720425D0/en
Priority claimed from GBGB1720426.4A external-priority patent/GB201720426D0/en
Application filed by Hummingbird Bioscience Holdings Pte Ltd filed Critical Hummingbird Bioscience Holdings Pte Ltd
Publication of SG11202003943YA publication Critical patent/SG11202003943YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202003943YA 2017-11-01 2018-11-01 Cd47 antigen-binding molecules SG11202003943YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1718101.7A GB201718101D0 (en) 2017-11-01 2017-11-01 CD47 and CD33 Antigen-binding molecules
GBGB1720425.6A GB201720425D0 (en) 2017-12-07 2017-12-07 CD47 and CD33 antigen-binding molecules
GBGB1720426.4A GB201720426D0 (en) 2017-12-07 2017-12-07 CD47 and BCMA antigen-binding molecules
PCT/EP2018/079931 WO2019086573A1 (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules

Publications (1)

Publication Number Publication Date
SG11202003943YA true SG11202003943YA (en) 2020-05-28

Family

ID=64316482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003943YA SG11202003943YA (en) 2017-11-01 2018-11-01 Cd47 antigen-binding molecules

Country Status (9)

Country Link
US (2) US20220298254A1 (en)
EP (1) EP3704157A1 (en)
JP (1) JP2021500926A (en)
KR (1) KR20200079511A (en)
CN (1) CN111417653A (en)
AU (1) AU2018358004A1 (en)
CA (1) CA3080860A1 (en)
SG (1) SG11202003943YA (en)
WO (1) WO2019086573A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500926A (en) 2017-11-01 2021-01-14 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド CD47 antigen-binding molecule
KR20220047277A (en) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 HIV Vaccines, and Methods of Making and Using the Same
CN112969715B (en) * 2019-08-21 2022-03-18 和铂医药(上海)有限责任公司 anti-CD 47 antigen binding protein and application thereof
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (en) 2019-10-31 2022-06-07 四十七公司 anti-CD 47 and anti-CD 20 based treatment of leukemia
CN117736207A (en) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 Diacylglycerol kinase modulating compounds
CN117964757A (en) 2020-02-14 2024-05-03 吉利德科学公司 Antibodies and fusion proteins that bind CCR8 and uses thereof
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
KR102557016B1 (en) * 2020-09-22 2023-07-20 비피진 주식회사 CD47 binder and liposome complex for treatment cancer
WO2022090556A1 (en) 2020-11-02 2022-05-05 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules
JP2024510989A (en) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ Vaccination methods and use of CD47 blockers
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20240269278A1 (en) * 2021-09-30 2024-08-15 Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group Anti-cd47 antibody for combined treatment of blood tumor
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
MX2024005066A (en) 2021-10-29 2024-05-24 Gilead Sciences Inc Cd73 compounds.
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
IL315083A (en) 2022-03-17 2024-10-01 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN116004636B (en) * 2023-01-10 2024-03-12 广西师范大学 Differential CD47 aptamer not binding red blood cells and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2477648T3 (en) 2009-09-15 2022-11-07 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
ES2743203T3 (en) 2012-02-06 2020-02-18 Inhibrx Inc CD47 antibodies and methods of use thereof
US11059910B2 (en) 2012-12-03 2021-07-13 Novimmune Sa Anti-CD47 antibodies and methods of use thereof
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
CN106414502A (en) 2014-02-27 2017-02-15 Ucl商务股份有限公司 April variants
CN104804093A (en) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 Single-domain antibody for CD47
CA2998644A1 (en) * 2015-09-18 2017-03-23 Arch Oncology, Inc. Therapeutic cd47 antibodies
EP3165536A1 (en) * 2015-11-09 2017-05-10 Ludwig-Maximilians-Universität München Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
SG11201805894YA (en) * 2016-01-11 2018-08-30 Forty Seven Inc Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
EP3454900A4 (en) 2016-05-09 2020-01-29 Celgene Corporation Cd47 antibodies and methods of use thereof
CN105950561A (en) 2016-05-26 2016-09-21 江苏杰晟生物科技有限公司 Products and preparation method of double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells
CN114773471A (en) * 2016-10-20 2022-07-22 天境生物科技(上海)有限公司 Novel CD47 monoclonal antibody and application thereof
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP2021500926A (en) 2017-11-01 2021-01-14 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド CD47 antigen-binding molecule

Also Published As

Publication number Publication date
US11685789B2 (en) 2023-06-27
JP2021500926A (en) 2021-01-14
KR20200079511A (en) 2020-07-03
CA3080860A1 (en) 2019-05-09
AU2018358004A1 (en) 2020-05-28
US20220298254A1 (en) 2022-09-22
US20220356250A1 (en) 2022-11-10
EP3704157A1 (en) 2020-09-09
WO2019086573A1 (en) 2019-05-09
CN111417653A (en) 2020-07-14

Similar Documents

Publication Publication Date Title
SG11202003943YA (en) Cd47 antigen-binding molecules
ZA201804326B (en) Therapeutic cd47 antibodies
HK1254310A1 (en) Anti-garp antibody
SG11202009361PA (en) Her3 antigen-binding molecules
GB201615617D0 (en) Small molecules
GB201709203D0 (en) Antigen-binding domain
GB201521858D0 (en) Small molecules
HK1250737A1 (en) Antibody molecules which bind cd79
DK3608337T3 (en) Bispecific T-cell-activating antigen-binding molecules
HK1250569A1 (en) Glycan-dependent immunotherapeutic molecules
GB201709970D0 (en) Bispecific antigen-binding molecules
IL256099A (en) Antibody
GB201522391D0 (en) Antibody molecules
IL268889A (en) Anti-epha4 antibody
GB201515351D0 (en) Antibody
GB201811403D0 (en) Antibody molecules
HUE057499T2 (en) Antibody
EP3714787C0 (en) Biosensor
HK1249549A1 (en) Antibody
GB201600871D0 (en) Antibody
GB201720426D0 (en) CD47 and BCMA antigen-binding molecules
PL3456736T3 (en) Antibody variants
IL273351A (en) Antibody variants
IL272951A (en) Antibody variants
GB201706043D0 (en) Small molecules